Development and validation of direct RT-LAMP for SARS-CoV-2

Abu Naser Mohon[1], Jana Hundt[1], Guido van Marle[1], Kanti Pabbaraju[2], Byron Berenger[2,3], Thomas Griener[3], Luiz Lisboa[3], Deirdre Church[3,4,5], Markus Czub[6], Alexander Greninger[7], Keith Jerome[8], Cody Doolan[9], Dylan R. Pillai [1,3,4,5]

1. Department of Microbiology, Immunology, and Infectious Diseases, University of Calgary, AB, Canada
2. Alberta Public Health Laboratory, Calgary, AB, Canada
3. Clinical Section of Microbiology, Alberta Precision Laboratories, Calgary, AB, Canada
4. Department Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada
5. Department of Medicine, University of Calgary, Calgary, AB, Canada
6. Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada
7. Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
8. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
9. Illucidx Inc., Calgary, AB, Canada

Abstract

We have developed a reverse-transcriptase loop mediated amplification (RT-LAMP) method targeting genes encoding the Spike (S) protein and RNA-dependent RNA polymerase (RdRP) of SARS-CoV-2. The LAMP assay achieves comparable limit of detection as commonly used RT-PCR protocols based on artificial targets, recombinant Sindbis virus, and clinical samples. Clinical validation of single-target (S gene) LAMP (N=120) showed a positive percent agreement (PPA) of 41/42 (97.62%) and negative percent agreement (NPA) of 77/78 (98.72%) compared to reference RT-PCR. Dual-target RT-LAMP (S and RdRP gene) achieved a PPA of 44/48 (91.97%) and NPA 72/72 (100%) when including discrepant samples. The assay can be performed without a formal extraction procedure, with lyophilized reagents which do need cold chain, and is amenable to point-of-care application with visual detection.

Corresponding author: Dylan Pillai MD, PhD, 9-3535 Research Road NW, 1W-416
Calgary, AB, Canada, T2L2K8, drpillai@ucalgary.ca, T: 403-770-3338, F: 403-770-3347

31 **Introduction**

32 Over the last several decades, we have witnessed the rise of both known and novel viruses, including
33 human immunodeficiency virus (HIV), SARS coronavirus (SARS-CoV), MERS-CoV, influenza H1N1, Ebola
34 virus (EBOV), Dengue (DENV), Chikungunya (CHIK), Zika (ZIKV), and most recently 2019 novel
35 coronavirus (SARS-CoV-2/COVID-19)(1). Most of these emerging viral infections have been triggered by a
36 direct zoonotic (animal-to-human) transmission event or enhancement, proliferation and spread of
37 vectors such as the mosquito in new geographic areas. In December 2019 and early January 2020, a
38 cluster of pneumonia cases from a novel coronavirus, SARS-CoV-2, was reported in Wuhan, China (2–4).

39 SARS-CoV-2 has now resulted in a global pandemic with the epicentre at the time of writing in Europe
40 and North America (5). A common theme in the public health response to COVID19 and similar threats is
41 the lack of rapidly deployable testing in the field to screen large numbers of individuals in exposed areas,
42 international ports of entry, and testing in quarantine locations such as the home residences, as well as
43 low-resourced areas (6). This hampers case finding and increases the number of individuals at risk of
44 exposure and infection. With the ease of travel across continents, delayed testing and lack of screening
45 programs in the field, global human-to-human transmission will continue at high rates. These factors
46 make a pandemic very difficult to contain. Early identification of the virus and rapid deployment of a
47 targeted point of care test (POCT) can stem the spread through immediate quarantine of infected
48 persons(7). We used existing viral genome sequences to develop a SARS-CoV-2 loop mediated
49 amplification (LAMP) assay for clinical use and evaluated whether an extraction-free and instrument-
50 free approach could be achieved(8, 9). POCT requires portability and low complexity without reliance on
51 sophisticated extraction and read-out instrumentation. Furthermore, LAMP relies on an alternate set of
52 reagent chemistry that does not depend on or hinder critical elements of the RT-PCR supply chain which

53 is now under duress (10). Our group has previously demonstrated the utility of LAMP for other
54 infectious agents like malaria and dengue (11–13).

55 **Materials and Methods**

56 *Patient samples and Ethics*

57 Clinical samples used in this study were standard nasopharyngeal (NP) swabs in viral transport medium
58 (VTM). Specifically, archival samples were sourced from the University of Washington, Seattle, USA and
59 extracted viral RNA from the Alberta Public Health Laboratory. Ethical approval for use of the archived
60 samples was obtained from the Conjoint Health Research Ethics Board (CHREB) of the University of
61 Calgary (REB20-0402). The use of de-identified specimens was deemed non-human subject work by the
62 University of Washington Institutional Review Board (IRB).

63 *LAMP primer design*

64 Genomic sequences (cDNA) of the SARS-CoV-2 were retrieved from the GenBank database
65 (https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/) and multiple sequence alignment analysis
66 (https://www.ebi.ac.uk/Tools/msa/clustalo/) was conducted with other related viruses. From the
67 multiple sequence alignment, several regions unique to the SARS CoV-2 were identified using our own
68 algorithms developed in collaboration with Illucidx Inc. (Calgary, AB). LAMP primer sets were designed
69 targeting unique regions of the Spike (S) protein gene, RNA-dependent RNA Polymerase gene (RdRP),
70 and parts of the Open Reading Frame (ORF) 1a/b. Five sets of LAMP primers were selected for
71 laboratory analysis, where Set 1 and Set 2 targeted the non-structural protein (nsp) 3 region in the
72 ORF1a/b gene and S protein gene, respectively; and Sets 3, 4, and 5 were designed to amplify different
73 regions of RdRP gene of SARS CoV-2 (Table 1). For the external LAMP amplification control, primers
74 were used against bacteriophage MS2 as previously described (14).

75 *Design of artificial viral target for LAMP assay verification*

76 Four fragments of specific SARS-Co-V2 regions (ORF1ab (nsp 3,10-11), RdRP (nsp 12), and spike (S)) were
77 synthesized by SGI-DNA Inc. (San Diego, CA). Fragments were ligated to make one large concatenated
78 DNA template using the BioXP3200 (SGI-DNA, San Diego, CA) automated Gibson assembly system. The
79 final template was 1097 base pairs long containing concatenated ORF1a/b (nsp 3)-Spike protein-RdRP
80 (nsp 12) - ORF1a/b (nsp 10-11) fragments together with flanking plasmid sequence in that order.

81 *Reverse transcription PCR (RT-PCR) assays used in this study*

82 The RT-PCR assays used in this study were performed according to previous publications for the E
83 gene(15) and N2 gene(16). The E gene RT-PCR was performed with modification according to the Alberta
84 Public Health Laboratory reference method (17). The modifications included the addition of GC clamps
85 at the 3' end of the primers and the shortening and addition of a minor groove binding (MGB) moiety to
86 the hydrolysis probe. Five (5) µL of input template was used to perform the RT-PCR reactions on the
87 same day when RT-LAMP was performed. A maximal Ct value cut-off of 40 was used to determine
88 positivity for all RT-PCR reactions.

89 *LAMP assay conditions*

90 The single-target LAMP reaction was conducted using a combination of Warmstart Rtx Reverse
91 Transcriptase (New England Biolab, Whitby, ON) with *Bst 2.0* Warmstart DNA Polymerase (New England
92 Biolab, Whitby, ON). In a 25 µL LAMP reaction mixture, 1.6 µM F1P and B1P, 0.8 µM LPF and LPB, 0.2 µM
93 F3 and B3 primer concentrations, 8mM $MgSO_4$, 1.4 mM dNTPs, 8 unit of *Bst* 2.0 WarmStart® DNA
94 Polymerase and 7.5 unit of Warm Start® reverse transcriptase were used. The assay was optimized with
95 pre-addition of 0.5µL of 50X SYBR green (Invitrogen, Burlington, ON) in the 25 µL reaction mixture. For
96 all LAMP experiments, 10 µL of template was used in the 25 µL reaction mixture. For dual-target LAMP,
97 identical reagent composition was used except the primers (6 per target) that were added at double

98 concentration and one half the volume for each primer set. Amplification was measured through
99 increased relative fluorescence units (RFU) per minute in the CFX-96 Real-Time PCR detection system
100 (Bio-Rad, Mississauga, ON) or fluorescence values on the QuantStudio 5 RT system (ThermoFisher,
101 Toronto, ON). RFU values above 100 on the CFX-96 instrument or greater than 100,000 on the
102 QuantStudio 5 instrument were considered positive when associated with a typical amplification curve
103 before a 30-minute reaction time. Each primer set was used to amplify the artificial viral DNA target at
104 different temperature (61°C, 63°C, and 65°C) for a maximum LAMP assay run time of 40 minutes.

105 *Visual detection of the LAMP without instrumentation*

106 A positive LAMP assay was detected visually by the pre-addition of 0.5µL colorimetric fluorescence
107 indicator (CFI). CFI was made up of the combination of 0.7% (v/v) 10000X Gelgreen (Biotium, Freemont,
108 CA) in 12 mM Hydroxynapthol blue resuspended in dH_20 (Sigma-Aldrich, Oakville, ON). After the 30-
109 minute LAMP reaction time, the tubes were exposed to blue LED light using a Blue Light Transilluminator
110 (New England Biogroup, Atkinson, NH) to visualize the green fluorescence.

111 *Lyophilized LAMP without the need for cold chain*

112 In order to determine if the LAMP primers and master mix could be lyophilized, oligonucleotides were
113 shipped to Pro-Lab Diagnostics (Toronto, Canada) and lyophilized with GspSSD2 isothermal master
114 mixture (Optigene, UK). The lyophilized primer, enzyme, master mix combination was hydrated in 15 µL
115 of resuspension buffer (Pro-Lab Diagnostics) to which 10 µL of the sample was added. Both direct LAMP
116 (see method described later) and kit-based RNA extractions were performed in this way.

117 *Limit of detection studies*

118 Limit of detection of the LAMP assay was evaluated in three different ways. Initially, copy number of the
119 synthesized DNA fragment was determined by comparing concentration and molecular weight.

120 Subsequently, the template solution was serially diluted to achieve a range from 5,000,000 to 5 copies
121 per reaction. These serially diluted templates were tested by all primers sets. Secondly, the extracted
122 RNA from one patient specimen was 10-fold serially diluted and tested with the LAMP assay and two RT-
123 PCR assays used by reference laboratories targeting both the E gene(15) and N2 gene(16). Finally, the
124 artificial template containing the targeted sequences of interest was cloned into Sindbis Virus (SV) viral
125 vector system (SINrep5) containing green fluorescent protein (EGFP) and then transfected into BHK-21
126 cell lines(18),(19). An approximate estimation of the viral titer was determined by comparing EGFP
127 expressing foci forming units in BHK-21 as described previously. EGFP forming units ranging from 10^6 –
128 10^8/mL were obtained for various recombinant virus stocks. Maintenance of the SARS/CoV2-targetted
129 sequences in the recombinant virus was confirmed using RT-PCR with primers targeting the flanking SV
130 sequences. Virus particles were serially diluted from 100 to 0.001 SV EGFP forming units per μL, and
131 RNA was extracted with the QiaAmp Viral RNA extraction kit (Qiagen, Toronto, ON). Extracted RNA was
132 subjected to TURBO™ DNase (ThermoFisher, Toronto, ON) digestion. Dilutions were subjected to LAMP
133 reactions as described above.

134 *Validation using clinical samples*

135 In total, 42 RT-PCR-positive clinical (n=32), contrived (n=10), and 78 negative NP swab samples were
136 tested in the single-target S gene LAMP validation study. In the negative panel, four common human
137 coronavirus RNA (strain 0C43, NL63, 229E, and HKU1), respiratory syncytial virus (RSV), and Influenza
138 H1N1 clinical samples were included to evaluate the specificity of the test. Contrived samples were
139 generated by inoculating the artificial gene DNA construct described earlier into VTM from NP swabs.
140 Extraction of RNA from clinical samples was performed using the NUCLISENS easyMAG system
141 (Biomerieux, Durham, NC) or QIAamp Viral RNA Mini Kit (Qiagen, Toronto, ON) depending on specimen
142 source. All samples in the set were tested simultaneously using the E gene RT-PCR described above and
143 S gene LAMP (primer set 2). Discrepant analysis was performed by performing the CDC N2 gene(16) RT-

144 PCR assay. For the LAMP assay, 10 µL of the RNA extract was used for each reaction. A second validation
145 study was performed for the dual-target LAMP (S gene and RdRP). Here, RT-PCR-positive clinical (n=34),
146 contrived (n=10), and 72 negative NP swab samples were tested. All LAMP reactions for the clinical
147 validation studies was performed using the combination of Warmstart Rtx Reverse Transcriptase with
148 Bst 2.0 Warmstart DNA Polymerase as described earlier.

149 *Direct LAMP assay without formal extraction*

150 A direct LAMP assay was also conducted to establish an extraction-free approach. In this scheme, the
151 LAMP reaction mixture was prepared without the enzymes. 9.5 µL reaction mixture containing all
152 reagents except the enzymes was added to 14 µL of the 10-fold serially diluted NP VTM sample. For
153 direct LAMP, VTM must be diluted 1:10 (v/v) with dH_20 prior to addition. The mixture was then heated
154 at 95°C for 3, 5, and 10 minutes to both inactivate virus and presumptively release viral RNA. Finally, *Bst*
155 2.0 WarmStart® DNA Polymerase (1 µL) and Warm Start® reverse transcriptase (0.5 µL) were directly
156 added to the reaction mixture and the LAMP assay was carried out as above. Due to evaporative loss,
157 boil steps should have excess volume to ensure adequate input template for LAMP reactions.

158 *In silico analysis of primer combinations to determine cross-reactivity*

159 A blast search alignment (https://blast.ncbi.nlm.nih.gov/Blast.cgi) for primers in set 2 (spike gene) and
160 set 3 (RdRP gene) were performed against a critical list of infectious agents that cause upper respiratory
161 tract infections. A nucleotide local alignment using BLASTn with the default parameters was performed
162 against the National Center of Biotechnology Information (NCBI) Nucleotide database.

163 **Results**

164 *Verification of SARS-CoV-2 LAMP primer sets on artificial gene targets*

165 In order to determine the limits of detection of the five LAMP primer sets designed for SARS-CoV-2,
166 experiments were conducted using an artificial gene target construct. Three targets (Figure 1) selected
167 were the Spike (S) protein gene, the RNA-dependent RNA polymerase (RdRP) region (nsp 12), and nsp 3
168 region in the open reading frame (ORF) 1a/b protein encoding gene sequence. Figure 2 shows the
169 amplification curves for the five primer sets used in this study. Based on time to positivity, primer sets 1,
170 2, and 3 demonstrated the fastest positive reaction time, suggesting optimal performance in the LAMP
171 assay at 50 copies of the artificial target per reaction. When tested at 5 copies per reaction, primer set 2
172 targeting the S gene showed the best limit of detection. An *in silico* analysis of primer set 2 (S gene) and
173 set 3 (RdRP) demonstrated no significant sequence alignment cross-reactivity with known upper
174 respiratory tract infectious pathogens (data not shown).

175 *Visual detection of SARS-CoV-2 LAMP amplification*

176 An advantage of LAMP is the ability to detect amplification with the naked eye either via the use of
177 colorimetric or fluorescent dyes. To test this, LAMP was conducted using the S gene LAMP primer set
178 using the artificial gene target. Figure 3 shows a positive test based on fluorescent detection using a blue
179 light emitting diode (LED). A serial dilution between 50 x 10^7 and 5 copies per reaction of the artificial
180 gene construct is shown with a limit of detection of 50 copies per reaction obtained. The LAMP assay
181 using enzyme GspSSD2 was also performed using a lyophilized master mix. Studies were performed with
182 both kit-based RNA extracted clinical samples as well as using the direct LAMP method described later.
183 These data showed that amplification occurred up to a 1000-fold dilution of a clinical sample with the
184 direct LAMP method (data not shown).

185 *Limit of detection studies using recombinant Sindbis virus (SV) containing SARS-CoV-2 targets*

186 In order to determine LOD based on viral titer, recombinant RNA viral vector from Sindbis virus (SV)
187 containing SARS-CoV-2 targets was generated. LAMP was performed using Set 2 (S gene) alone and in

188 combination with Set 3 (RdRP region (nsp 12)). The primer sets in question achieved a LOD of 0.1-1.0 SV
189 EGFP forming units per μL for the S gene alone and the dual-target LAMP amplifying both S and RdRP
190 genes in a single reaction (Table 2). One SV EGFP focus forming unit (FFU) roughly corresponds to 1.0
191 infectious viral particle given the assumption that one virus particle infects one cell.

192 *Direct LAMP detection of SARS-CoV-2 without formal extraction*

193 Given extraction reagent supply chain shortages, we tested the ability of LAMP using the S gene to
194 amplify a SARS-CoV-2 positive nasopharyngeal swab specimen without a formal extraction procedure.
195 The VTM was heated at 95°C for 3, 5 and 10 minutes and then subjected to the S gene LAMP procedure
196 in a serial dilution experiment. This experiment was performed in a head-to-head comparison with the
197 same specimen tested after formal extraction. Figure 4 demonstrates that amplification occurred with
198 direct LAMP up to a dilution of 100,000-fold with a 95°C for 3 minutes heat step in a single experiment.
199 Table 3 shows the data for direct LAMP compared to LAMP and RT-PCR from RNA extracts in triplicate
200 experiments. Reproducible amplification with direct LAMP (95°C for 3 minutes) occurred at a dilution
201 factor of 1,000-fold, whereas LAMP from an RNA extract was successful reproducibly at a dilution of
202 100,000-fold.

203 *Limit of detection studies using SARS-CoV-2 LAMP on nasopharyngeal swab clinical samples*

204 Serial dilution experiments were conducted using a single positive SARS-CoV-2 nasopharyngeal swab
205 specimen. The viral transport media (VTM) was diluted serially between 10 to 1,000,000-fold. The
206 dilutions were tested in triplicate to determine the results of LAMP and two reference RT-PCR methods
207 (Envelope [E] gene and Nucleocapsid [N] 2 gene). Both RT-PCR and the RT-LAMP (S gene) amplified the
208 target up to a dilution of 100,000 in a head-to-head comparison, suggesting equal LOD (data not shown).
209 The same experiment was conducted comparing E gene RT-PCR to RT-LAMP (dual-target S and RdRP
210 gene) as well as a direct RT-LAMP (dual-target S and RdRP gene) without formal extraction (boil method)

211 on a separate specimen. These data are shown in Figure 5 and Table 4. Reproducible amplification
212 occurred at 1000-fold dilution for RT-PCR (E gene) and RT-LAMP. Direct-LAMP amplified reproducibly at
213 a 100-fold dilution for this sample.

214 *Clinical validation of SARS-CoV-2 LAMP using nasopharyngeal swab samples*

215 A sample set of nasopharyngeal swabs (n=108) from COVID-positive, COVID-negative, together with
216 samples for other respiratory viruses were used to validate the S gene LAMP primer set (Table 5). Given
217 no gold standard exists, percent positive agreement (PPA) and negative percent agreement (NPA) were
218 calculated. Reference methods included RT-PCR (E gene and N2 gene) methods employed by reference
219 laboratories. Using the RT-PCR (E gene) as a reference standard, there was 41/42 (97.62% (95% CI 87.43
220 - 99.94)) PPA and 77/78 (98.72% (95% CI 93.06 - 99.97)) NPA for the S gene LAMP. No cross-reactivity
221 was observed for human coronaviruses (HCoV) OC43, 229E, NL63, and HKU1 or influenza virus A (H1N1)
222 pdm09. Resolution of discrepant results (Table 6) revealed that one falsely positive LAMP result was
223 positive based on the original RT-PCR result reported at the time of clinical testing and therefore
224 represented a true positive that may be due to sample decay in storage. The second falsely negative
225 sample was positive by all methods including the RdRP LAMP primer set and was deemed a false
226 negative in the final analysis. In order to eliminate the concern for S gene false negatives, dual-target S
227 and RdRP LAMP was performed to increase clinical sensitivity. This second clinical sample set
228 intentionally included low positive (high Ct value) specimens. Table 7 demonstrates PPA of 44/48
229 (91.67% (95% CI 80.02 - 97.68)) and NPA 72/72 (100.00% (95% CI 95.01 - 100.00)) for the dual LAMP
230 compared to the RT-PCR E gene reference method. Discrepant analysis (Table 8) revealed that all four
231 falsely negative samples by LAMP were in fact positive by the CDC N2 RT-PCR, confirming the false
232 negative status. The four discrepant specimens were repeated with single-target S gene LAMP and were
233 also negative.

234

235 **Discussion**

236 The global pandemic with SARS-CoV-2 has resulted in the need for diagnostic test development at a
237 scale never seen before. Rapid deployment of validated laboratory-developed diagnostic tests or
238 commercial tests was essential to the containment of the virus as it allows for self-quarantine measures
239 to be imposed in a strategic fashion before widespread community transmission occurs (6, 7) .
240 Diagnostic tests have to be analytically sensitive in order to not to miss any cases in the acute phase of
241 viremia (11). As such, NAATs serve this purpose. In particular, RT-PCR has been employed as the primary
242 diagnostic counter-measure (20). However, reagent supply chains for key items are under immense
243 pressure. Local solutions to reagent sources have become paramount because barriers to trade of these
244 selected items have been a concern.

245 We noted that a one false negative occurred with single-target LAMP (S gene) for a lower Ct value
246 sample that may be due to genetic polymorphism at key residues where LAMP primers bind. This issue
247 was overcome by using two targets (S and RdRP genes) simultaneously. The single and dua-target RT-
248 LAMP test for SARS-CoV-2 has comparable analytical sensitivity and achieved excellent agreement with
249 the reference method. We noted that at high Ct value (>35), and presumably low-level infection, E gene
250 RT-PCR identified specimens that LAMP did not. This suggests the LOD of the RT-PCR used in this study
251 may be superior to LAMP for these low positives. However, we note that samples with E gene RT-PCR Ct
252 values greater than 35 are relatively rare (~1%) at our reference laboratory (our unpublished
253 observations). Increasing LAMP reaction times may reduce false negatives, but also lead to spurious
254 amplification. The clinical relevance of these low positives is still not well understood and could
255 represent early infection during the incubation period, late infection after the initial viral peak, or
256 asymptomatic carriage. The transmissibility of these low positives to others is also not well understood.

257 Moreover, if we assume an overall prevalence of 5%, the negative predictive value of LAMP is 99.56%
258 (95% CI 98.89 - 99.83) and positive predictive value is 100%. These values clearly support the use of
259 LAMP as an alternative NAAT.

260 LAMP does not rely on the same reagents as RT-PCR and thus alleviates pressure on key supply chain
261 items. The LAMP method is amenable to high throughput testing in either 96-well or 384-well. The assay
262 is also able to detect SARS-CoV-2 in VTM without the need for a kit-based RNA extraction method
263 relying on commercial reagents. However, we noted a 2-log drop in analytical sensitivity when direct
264 LAMP was performed following this heat step. The drop in analytical sensitivity will only affect low-level
265 viral load specimens. This is still within a good range compared to RT-PCR using RNA isolation. We
266 believe that addition of a buffer to stabilize the RNA-enzyme complex in the LAMP reaction may further
267 enhance this extraction-free approach. This needs to be tested. The heat step at 95ºC for 3 minutes
268 should significantly inactivate the virus permitting safe operation of the assay in a Class II biosafety
269 cabinet (21). Taken together, these data support the use of LAMP chemistry as an alternate method for
270 laboratory developed NAATs.

271 Our studies with a LAMP enzyme called GspSSD2 also provided encouraging results. These data
272 demonstrated that lyophilized GspSSD2 and reagents are able to amplify SARS-CoV-2 directly from a
273 specimen without a kit-based RNA extraction. Additionally, visual detection with a simple blue LED light
274 is able to discriminate positive from negative. These features are particularly useful for resource-limited
275 settings without sophisticated laboratory infrastructure or where the cost of or access to kit-based
276 reagents and equipment are prohibitive. Further studies are required to clinically validate this low-cost
277 approach.

278 Limitations of the study include not testing other sample types such as alternate swabs, nasal washes,
279 oropharyngeal samples, sputum, or stool. This work is ongoing with a special emphasis on swab-free

280 testing. Also formal SARS-CoV-2 viral titers were not calculated in the limit of detection studies.
281 Nevertheless, LAMP presents a much needed alternative approach to SARS-CoV-2 diagnostic testing that
282 is available for deployment immediately in a LDT format as it relies on other key reagents that do not
283 cannibalize RT-PCR reagents. Ultimately, the aim is to port LAMP chemistry on a stand-alone microfluidic
284 device POCT to be deployed in the community, either at ports of entry, homes, pharmacies, or resource-
285 limited settings.

286 **Acknowledgments**

287 Dr. Ranmalee Amarasekara for expert technical assistance, Daniel Castaneda Mogollon for performing
288 bioinformatics analysis, and Omar Abdullah for research analytical support.

289 **Funding Statement**

290 Funding for this study was obtained from the Canadian Institutes for Health Research (NFRFR-2019-
291 00015, DRP) and Genome Canada (DRP), and from the M.J. Murdock Charitable Trust (KRJ).

292 **Conflicts of Interest**

293 ANM and DRP have a patent on LAMP technology. CD is an employee of Illucidx Inc.

294

295

296

297

298

299

300

301 **References**

302 1. Reperant LA, Osterhaus ADME. 2017. AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next?
303 Vaccine 35:4470–4474.

304 2. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang
305 N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu
306 H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF,
307 Cowling BJ, Yang B, Leung GM, Feng Z. 2020. Early Transmission Dynamics in Wuhan, China, of Novel
308 Coronavirus-Infected Pneumonia. N Engl J Med 382:1199–1207.

309 3. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, Chen H-D,
310 Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang X, Zheng X-S, Zhao K, Chen Q-J, Deng F,
311 Liu L-L, Yan B, Zhan F-X, Wang Y-Y, Xiao G-F, Shi Z-L. 2020. A pneumonia outbreak associated with a new
312 coronavirus of probable bat origin. Nature 579:270–273.

313 4. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H, Pei Y-Y, Yuan M-L,
314 Zhang Y-L, Dai F-H, Liu Y, Wang Q-M, Zheng J-J, Xu L, Holmes EC, Zhang Y-Z. 2020. A new coronavirus
315 associated with human respiratory disease in China. Nature 579:265–269.

316 5. CDC COVID-19 Response Team. 2020. Severe Outcomes Among Patients with Coronavirus
317 Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep
318 69:343–346.

319 6. Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, Dittrich S, Yansouni CP.
320 2020. Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative
321 Review. Ann Intern Med.

322 7. Nguyen T, Duong Bang D, Wolff A. 2020. 2019 Novel Coronavirus Disease (COVID-19): Paving the
323 Road for Rapid Detection and Point-of-Care Diagnostics. Micromachines 11.

324 8. Forster P, Forster L, Renfrew C, Forster M. 2020. Phylogenetic network analysis of SARS-CoV-2
325 genomes. Proc Natl Acad Sci U S A.

326 9. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F,
327 Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ,
328 Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. 2020. Genomic characterisation and
329 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet Lond
330 Engl 395:565–574.

331 10. Ivanov D. 2020. Predicting the impacts of epidemic outbreaks on global supply chains: A
332 simulation-based analysis on the coronavirus outbreak (COVID-19/SARS-CoV-2) case. Transp Res Part E
333 Logist Transp Rev 136:101922.

334 11. Sigera PC, Amarasekara R, Rodrigo C, Rajapakse S, Weeratunga P, De Silva NL, Huang CH, Sahoo
335 MK, Pinsky BA, Pillai DR, Tissera HA, Jayasinghe S, Handunnetti S, Fernando SD. 2019. Risk prediction for

336 severe disease and better diagnostic accuracy in early dengue infection; the Colombo dengue study.
337 BMC Infect Dis 19:680.

338 12. Mohon AN, Getie S, Jahan N, Alam MS, Pillai DR. 2019. Ultrasensitive loop mediated isothermal
339 amplification (US-LAMP) to detect malaria for elimination. Malar J 18:350.

340 13. Girma S, Cheaveau J, Mohon AN, Marasinghe D, Legese R, Balasingam N, Abera A, Feleke SM,
341 Golassa L, Pillai DR. 2018. Prevalence and epidemiological characteristics of asymptomatic malaria based
342 on ultrasensitive diagnostics: A cross-sectional study. Clin Infect Dis Off Publ Infect Dis Soc Am.

343 14. Benzine JW, Brown KM, Agans KN, Godiska R, Mire CE, Gowda K, Converse B, Geisbert TW,
344 Mead DA, Chander Y. 2016. Molecular Diagnostic Field Test for Point-of-Care Detection of Ebola Virus
345 Directly From Blood. J Infect Dis 214:S234–S242.

346 15. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, Bleicker T, Brünink S,
347 Schneider J, Schmidt ML, Mulders DGJC, Haagmans BL, van der Veer B, van den Brink S, Wijsman L,
348 Goderski G, Romette J-L, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MPG, Drosten
349 C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill Bull Eur Sur
350 Mal Transm Eur Commun Dis Bull 25.

351 16. 2020. https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html.
352 Centers for Disease Control and Prevention.

353 17. https://www.albertahealthservices.ca/assets/wf/lab/wf-lab-bulletin-COVID-19-test-
354 performance.pdf.

355 18. van Marle G, Ethier J, Silva C, Mac Vicar BA, Power C. 2003. Human immunodeficiency virus type
356 1 envelope-mediated neuropathogenesis: targeted gene delivery by a Sindbis virus expression vector.
357 Virology 309:61–74.

358 19. Bredenbeek PJ, Frolov I, Rice CM, Schlesinger S. 1993. Sindbis virus expression vectors:
359 packaging of RNA replicons by using defective helper RNAs. J Virol 67:6439–6446.

360 20. Nalla AK, Casto AM, Huang M-LW, Perchetti GA, Sampoleo R, Shrestha L, Wei Y, Zhu H, Jerome
361 KR, Greninger AL. 2020. Comparative Performance of SARS-CoV-2 Detection Assays using Seven
362 Different Primer/Probe Sets and One Assay Kit. J Clin Microbiol.

363 21. Darnell MER, Subbarao K, Feinstone SM, Taylor DR. 2004. Inactivation of the coronavirus that
364 induces severe acute respiratory syndrome, SARS-CoV. J Virol Methods 121:85–91.

365

366

367

368

369 **Figures**

370

371 Figure 1: Map of the gene fragments from SARS-Co-V2 (Genbank ID MT2078.1) that were used for
372 synthesizing the genetic construct template. Fragments of ORF1a/b [nsp 3] (3064-3285), ORF1a/b [nsp
373 10-11] (13328-13622), ORF1a/b RdRP [nsp 12] (15258-15445), and Spike gene (22153-22368) were
374 concatenated into a single artificial construct. A second template including the E gene was also made for
375 the purposes of testing the E gene RT-PCR.



376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396 Figure 2: Limit of detection of RT-LAMP primer sets designed to detect the SARS-CoV-2 artificial DNA
397 construct. These data are representative of an experiment performed in triplicate at (A) 500 and (B) 50
398 copies. Amplification curves for all 5 primer sets are shown: Set 1 (ORF1ab); Set 2 (S gene); and Set 3, 4,
399 and 5 (RdRP). Based on these experiments, a cut off 30 minutes reaction time was determined for
400 specific amplification. Fluorescence (QuantStudio 5) on the y-axis is plotted in relation to reaction time
401 (minutes).
402



403

404

405

406

407

408

409

410

411

412

413

414

415

416 Figure 3: Photograph of S gene RT-LAMP (Set 2) performed on the artificial DNA construct. Fluorescence
417 can be detected by naked eye after excitation of gel green in the reaction with a blue LED light. A serial
418 10-fold dilution is shown from 5 x 10^7 copies to 5 copies of the gene construct in this representative
419 experiment (left to right). The last two tubes on the right are negative template controls. A reaction time
420 was set at 30 minutes.
421

422



423

424

425

426

427

428

429

430

431

432

433

434

Figure 4: Single-target (S gene) RT-LAMP amplification of SARS-CoV-2 spike gene from NP swab sample (E gene Ct 21.29) using a simple heat step. A representative direct LAMP experiment is compared to a kit-based extracted RNA (A) for serial dilutions of the neat sample. Heat inactivation without formal extraction is shown in (B) 95°C for 3 minutes (C) 95°C for 5 minutes and (D) 95°C for 10 minutes. Relative fluorescence units (CFX-96) on the y-axis is plotted in relation to reaction time (minutes).



455 Figure 5: Serial dilution studies of a clinical sample (NP swab in VTM, E gene Ct 25.6) comparing the limit
456 of detection of Envelope (E) gene RT-PCR (n=6), S gene + RdRP gene RT-LAMP (n=9) and S gene + RdRP
457 gene direct RT-LAMP (n=9). Cycle threshold (Ct) value (RT-PCR) or time in minutes (LAMP) shown on y-
458 axis. No virus was detected at a dilution of 1 x 10^5 from the original neat sample. Standard deviation of
459 the mean indicated in error bars if more than two values existed.
460

461

462
463
464



465
466
467
468
469

470

471

472

473

474

475

476

477

478

479

480 **Tables:**

481 Table 1: Primer sets used in this study to perform RT-LAMP. All 5 primer sets are shown: Set 1 (ORF1a/b,
482 nsp3); Set 2 (S gene); and Set 3, 4, and 5 (RdRP).

483

Primer name	Sequence
S1-F3	AGTTTGAGCCATCAACTCA
S1-B3:	TGAACCTCAACAATTGTTTGA
S1-F1P	CAGGTTGAAGAGCAGCAGAAGTGTACTGAAGATGATTACCAAGG
S1-B1P	AGCAAGAAGAAGATTGGTTAGATGATGTCTGATTGTCCTCACTG
S1-LPF	GGCACCAAATTCCAAAGGT
S1-LPB	AACTGTTGGTCAACAAGACGG
S2-F3	ATTCTAAGCACACGCCTAT
S2-B3	GAAGATAACCCACATAATAAGCT
S2-F1P	ACCTATTGGCAAATCTACCAATGGTTTAGTGCGTGATCTCCCT
S2-B1P	ATCACTAGGTTTCAAACTTTACTTGCCTGTCCAACCTGAAGAAGA
S2-LPF	TTCTAAAGCCGAAAAACCCTG
S2-LPB	CATAGAAGTTATTTGACTCCTGGTG
S3-F3	CACCTTATGGGTTGGGATT
S3-B3	AACATATAGTGAACCGCCA
S3-F1P	GTTTGCGAGCAAGAACAAGTGAATGTGATAGAGCCATGCC
S3-B1P	ATACAACGTGTTGTAGCTTGTCACACATGACCATTTCACTCAA
S3-LPF	GGCCATAATTCTAAGCATGTTA
S3-LPB	ATTAGCTAATGAGTGTGCTCAAGTA
S4-F3	ACATGCTTAGAATTATGGCC
S4-B3	GCTTGACAAATGTTAAAAACACT
S4-F1P	TTGAGCACACTCATTAGCTAATCTATCACTTGTTCTTGCTCGCA
S4-B1P	GAGTGAAATGGTCATGTGTGGCGCATAAGCAGTTGTGGCA
S4-LPF	GACAAGCTACAACACGTTGTATGT

S4-LPB	ACTATATGTTAAACCAGGTGGAACC
S5-F3	ATGGCCTCACTTGTTCTT
S5-B3	TAACATTGGCCGTGACAG
S5-F1P	TTGAGCACACTCATTAGCTAATCTATGCTCGCAAACATACAACG
S5-B1P	GTCATGTGTGGCGGTTCACTACACTATTAGCATAAGCAGTTG
S5-LPF	ACGGTGTGACAAGCTACAACA
S5-LPB	CCAGGTGGAACCTCATCAGGAG

484

485

486

487

488 Table 2: RT-LAMP assay results on serially diluted recombinant SV virus containing the artificial construct
489 now expressed as RNA. Positive tested replicates/total number of replicates is shown in relation to the
490 approximate viral titer for both single-target (S gene) and dual-target (S and RdRP gene) LAMP reactions.

491

Approximate viral titer/µL	S gene Single-target RT-LAMP	S gene and RdRP gene Dual-Target RT-LAMP
100	3/3	3/3
10	3/3	3/3
1	3/3	3/3
0.1	2/3	2/3
0.01	0/3	1/3
0.001	0/3	0/3

492 Table 3: Single-target (S gene) RT-LAMP assay results on a NP swab VTM sample (E gene Ct 21.29) containing SARS-Co-V2 compared to RT-LAMP
493 and RT-PCR after kit-based RNA extraction. Positive tested replicates/total number of replicates for a single representative triplicate experiment
494 is shown. Dilutions are based on 10-fold serial dilutions from a neat NP VTM sample. Kit-based extraction is compared to direct RT-LAMP
495 procedures including a heat step.

496

Sample dilution factor	E gene RNA extract RT-PCR	N2 gene RNA extract RT-PCR	RT-LAMP RNA extract	Direct RT-LAMP 10 min/95°C	Direct RT-LAMP 5 min/95°C	Direct RT-LAMP 3 min/ 95°C
10	3/3	3/3	3/3	3/3	3/3	3/3
100	3/3	3/3	3/3	3/3	3/3	3/3
1000	3/3	3/3	2/3	1/3	2/3	2/3
10000	3/3	3/3	3/3	0/3	0/3	1/3
100000	2/3	2/3	2/3	0/3	0/3	1/3

497

498

499

500

501

502

503

504

505

506 Table 4: Dual-target RT-LAMP (S and RdRP gene) assay results on a NP VTM sample (E gene Ct 25.6) containing SARS-Co-V2 compared to RT-PCR
507 after kit-based RNA extraction and directly from a sample. Positive tested replicates/total number of replicates from repeated triplicate
508 experiments is shown. Dilutions are based on 10-fold serial dilutions from a neat NP VTM sample.

509

Sample dilution factor	E gene RNA extract RT-PCR	Dual RT-LAMP RNA extract	Direct dual RT-LAMP 3 min/ 95°C
10	6/6	9/9	9/9
100	6/6	9/9	9/9
1000	6/6	5/9	1/9
10000	1/6	1/9	0/9
100000	0/6	0/9	0/9

510 Table 5: Validation of RT-LAMP (S gene) compared to RT-PCR (E gene) for clinical samples (NP swabs),
511 contrived samples, and negative control samples. PPA - positive percent agreement; NPA - negative
512 percent agreement

513

RT-LAMP (S gene)	RT-PCR (E gene)		Total
	Positive	Negative	
Positive	41	1	42
Negative	1	77	78
Total	42	78	120
PPA	97.67% (95% CI 87.43 - 99.94)		
NPA	98.72% (95% CI 93.06 - 99.97)		

514

515

516 Table 6: Discrepant analysis for single-target (S gene) RT-LAMP from the clinical validation data
517 set.

518

Sample number	Original RT-PCR (E gene)	Repeat RT-PCR (E gene)	RT-LAMP (S gene)	RT-LAMP (RdRP)	CDC RT-PCR (N2 gene)	CDC RT-PCR Ct value	Final
Sample 4	Positive	Negative	Positive	Negative	Negative	N/A	Positive
Sample 7	Positive	Positive	Negative	Positive	Positive	26.8	Positive

519

520

521 Table 7: Validation of dual-target RT-LAMP (S gene and RdRP genes) using a validation set of
522 clinical samples. PPA - positive percent agreement; NPA - negative percent agreement

RT-LAMP (S + RdRP)	RT-PCR (E gene)		Total
	Positive	Negative	
Positive	44	0	44
Negative	4	72	76
Total	48	72	120
PPA	91.67% (95% CI 80.02 - 97.68)		
NPA	100.00% (95% CI 95.01 - 100.00)		

523 Table 8: Discrepant analysis for dual-target (S + RdRP gene) RT-LAMP for samples with high Ct
524 values from the clinical validation data

525

Sample number	Original RT-PCR (E gene)	Repeat RT-PCR (E gene)	RT-LAMP (S + RdRP gene)	RT-LAMP (S gene)	CDC RT-PCR (N2 gene)	CDC RT-PCR Ct value	Final
Sample A7	Positive	Positive	Negative	Negative	Positive	38.36	Positive
Sample A8	Positive	Positive	Negative	Negative	Positive	36.19	Positive
Sample B7	Positive	Positive	Negative	Negative	Positive	36.41	Positive
Sample D5	Positive	Positive	Negative	Negative	Positive	35.39	Positive

526